Biologic Gout Drug Fails the FDA Panel Sniff Test
May 9, 2012|Rheumatology News
Author and Disclosure Information
FROM A MEETING OF THE FOOD AND DRUG ADMINISTRATION'S ARTHRITIS ADVISORY COMMITTEE
The FDA usually follows the recommendations of its advisory panels. The panelists have been cleared of potential conflicts of interest related to the topic of the meeting. Occasionally, a panelist may be given a waiver but not at this meeting.
*Correction, 5/9/2012: A previous version of this story misstated the panelists' concern about the drug's potential to cause cancer.
